Phase 1 Gastrointestinal Stromal Tumor Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
Gastrointestinal Stromal Tumors
University of California, San Diego18 enrolled1 locationNCT07171203
Recruiting
Phase 1Phase 2
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckOvarian Neoplasms+8 more
Cancer Research UK167 enrolled4 locationsNCT06380816
Recruiting
Phase 1
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
Metastatic CancerGastrointestinal NeoplasmsGastrointestinal Diseases+2 more
IDRX, Inc., a wholly owned subsidiary of GSK, LLC278 enrolled31 locationsNCT05489237
Recruiting
Phase 1
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Solid Tumor, AdultGastrointestinal Stromal Tumor (GIST)
Ascentage Pharma Group Inc.100 enrolled6 locationsNCT03594422
Recruiting
Phase 1
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Gastrointestinal Stromal Tumor (GIST)Gastrointestinal Stromal NeoplasmGastrointestinal Stromal Cancer+2 more
Kura Oncology, Inc.157 enrolled32 locationsNCT06655246
Recruiting
Phase 1Phase 2
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC120 enrolled10 locationsNCT06630234
Recruiting
Phase 1
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Uveal MelanomaNeuroendocrine TumorsGastrointestinal Stromal Tumors+4 more
Novelty Nobility, Inc.67 enrolled5 locationsNCT06805825